🧬 Aging Wiki

age-crosslink-breakers

Properties1
aliasesAGE breakers, glycation crosslink breakers, GlycoSENS pharmacology, alagebrium class, ALT-711 class

24 min read

AGE Crosslink Breakers

Pharmacological agents designed to cleave covalent advanced glycation end-product (AGE) crosslinks in long-lived extracellular matrix (ECM) proteins — specifically in type I collagen of arteries, skin dermis, tendon, and cardiac interstitium. This is a damage-repair intervention class in the SENS GlycoSENS framework: unlike most aging interventions that modulate cellular signaling pathways, AGE-crosslink breakers aim to reverse accumulated structural damage to the ECM.

Despite roughly 25 years of academic and pharmaceutical interest, no clinically deployed AGE-crosslink-breaking agent exists. The clinical program most advanced to date — alagebrium (ALT-711) — failed its Phase 3 pivotal trial in 2011, and subsequent analysis revealed it may never have been targeting the right crosslink. The active research front is the Spiegel Lab at Yale / Revel Pharmaceuticals glucosepane-specific program, which is still preclinical as of mid-2026 and has encountered a reported reproducibility setback.

For upstream biology of AGE formation and tissue distribution, see advanced-glycation-end-products. For the specific target crosslink chemistry, see glucosepane.

Why AGE-breaking matters

Advanced glycation end-products (AGEs) accumulate in long-lived proteins — particularly type I collagen in arteries, skin, and tendons — through the irreversible Maillard reaction. The dominant irreversible crosslink in adult human ECM is glucosepane — a covalent Lys–Arg bridge that forms between adjacent collagen chains and is present at concentrations 10–100× that of the next most abundant crosslink (pentosidine) in non-diabetic individuals over 90 1.

These crosslinks are essentially permanent: no mammalian enzyme cleaves glucosepane. Because long-lived structural proteins cannot replace their crosslinked forms fast enough, the crosslink burden accumulates monotonically with age, causing:

  • Arterial stiffening — reduced compliance of the elastic collagen-elastin wall in large arteries; rising pulse wave velocity and pulse pressure; mechanistic contributor to age-related isolated systolic hypertension 2
  • Cardiac diastolic dysfunction — crosslinking of myocardial interstitial and perivascular basement-membrane collagen impairs ventricular filling; proposed driver of HFpEF
  • Skin elasticity loss — crosslinked dermal collagen resists MMP-mediated remodeling, reducing skin extensibility and contributing to visible aging
  • Tendon/cartilage stiffening and fragility — glucosepane crosslinks overlap integrin, proteoglycan, and collagenase binding sites on the collagen triple helix, physically blocking enzymatic remodeling 3
  • Basement membrane thickening — impairs capillary function in kidney, retina, and peripheral nerves; amplified by diabetes

The SENS Research Foundation categorizes this damage as GlycoSENS — extracellular “junk” requiring enzymatic removal rather than metabolic manipulation. See sens-damage-categories.

Hallmark mapping: loss-of-proteostasis is the closest López-Otín hallmark (ECM structural-protein homeostasis failure); downstream mechanosignaling effects map to altered-intercellular-communication via integrin/YAP/TAZ axis dysregulation in stiffened ECM. ECM crosslink accumulation does not have a dedicated hallmark in the 2013/2023 López-Otín framework. See advanced-glycation-end-products § Aging context.

Natural enzymatic AGE clearance — three-tier defense framework

Biology does possess enzymatic defenses against glycation — but they are insufficient for the dominant (mature-crosslink) compartment of aging ECM. Understanding which tiers exist, what they cover, and where they stop is essential context for evaluating why pharmacological AGE-crosslink breakers are necessary and why they remain undeveloped.

Tier 1 — Reactive dicarbonyl detoxification (prevents AGE formation; universal)

The first and most evolutionarily ancient line of defense does not reverse glycation — it prevents it by eliminating the most reactive precursors before they can react with protein.

glo1 + GLO2 + glutathione (glyoxalase system): Glyoxalase-1 catalyzes the isomerization of the methylglyoxal-glutathione hemithioacetal to S-D-lactoylglutathione; GLO2 hydrolyzes it to D-lactate + GSH. The system detoxifies methylglyoxal — the most reactive endogenous α-dicarbonyl and the principal precursor to MG-H1, CEL, MOLD, and argpyrimidine. The glyoxalase system is present in all life forms from bacteria to humans and constitutes the dominant evolutionary AGE-defense mechanism. Intracellular methylglyoxal is maintained at ~1–5 µM steady state almost entirely due to GLO1 flux 4.

Secondary Tier 1 enzymes: Aldo-keto reductase (AKR1B1) and aldehyde dehydrogenase (ALDH2) provide subsidiary methylglyoxal clearance via reduction and oxidation respectively. These are quantitatively minor but functionally relevant in specific tissues (AKR1B1 in lens/nerve; ALDH2 in myocardium/liver).

AGE-prevention, not reversal. Tier 1 defense acts strictly at the pre-modification stage. Once MG or glyoxal has reacted with a protein lysine/arginine, Tier 1 enzymes have no further role.

Age-related decline: GLO1 activity decreases with age in multiple tissues (Thornalley group) 4. This age-related GLO1 decline is proposed as a contributor to the monotonic rise in tissue AGE burden observed even in normoglycemic aging.

Tier 2 — Early-glycation Amadori-product reversal (acts on Stage 2; not on mature crosslinks)

Tier 2 enzymes act after initial glycation has occurred — specifically on Amadori products (fructosyl-lysine; Stage 2 Maillard) — converting them back to free protein before they progress to irreversible mature AGEs.

Mammalian fn3k (fructosamine-3-kinase): The only well-characterized mammalian deglycation enzyme. FN3K phosphorylates the C3-hydroxyl of fructosyl-lysine; the product (fructosamine-3-phosphate) is unstable and decomposes to free protein amine + 3-deoxyglucosone + Pi, restoring the native lysine. FN3K is active on small intracellular proteins (erythrocytes, lens crystallins, liver, kidney, brain); its expression is primarily intracellular. Critical limitation: FN3K cannot reach long-lived ECM collagen (dermis, arterial wall, tendon) — the compartment where glucosepane and pentosidine accumulate. FN3K-knockout mice show ~2.5-fold elevated erythrocyte fructosamine but appear phenotypically normal under normoglycemia, suggesting Tier 2 rescue is modest under normal conditions 5.

Fungal/bacterial FAOD: FAD-dependent oxidative deglycation; commercially used in HbA1c diagnostics for decades (cleaves fructosyl-Val-His at HbA1c N-terminus). Broader therapeutic interest arose from Delanghe et al. 2024, which reported that FAOD treatment of glycolaldehyde-glycated porcine retinas reduced AGE autofluorescence (p = 0.001) and reduced drusen surface area to 45 ± 21% of control in human AMD retinal sections 6. Mass spectrometry in that study revealed broader substrate scope than FN3K: FAOD reportedly acted on fructosyl-lysine, CML, CEL, and imidazolone — all non-crosslink AGE adducts. Agmatine (4-aminobutyl-guanidine) was unexpectedly released, suggesting guanidino-bond cleavage. This is the first natural enzyme reported to act on mature CML — a significant result for the carboxymethyl-lysine field. Caveats: abstract-only verification for Delanghe 2024; no independent replication; glucosepane and pentosidine cleavage NOT reported; CML and CEL are monovalent adducts, not crosslinks.

Tier 3 — Mature-crosslink cleavage (no known natural enzyme)

No characterized enzyme — mammalian, fungal, bacterial, or archaeal — is known to cleave glucosepane or pentosidine crosslinks in protein. This is the crux of the GlycoSENS problem and the motivation for the Revel Pharmaceuticals program.

The initial Revel/Spiegel functional-metagenomics candidates claimed to cleave glucosepane in vitro, but their activity could not be reproduced — prompting Revel’s strategic pivot to a multi-crosslink portfolio approach 7. As of 2026-05-20, no published in-vivo glucosepane-cleavage efficacy exists from any program.

Why natural evolution may not have produced glucosepane breakers

The absence of a natural glucosepane-cleaving enzyme is not a gap in our knowledge of existing enzymes — it likely reflects a genuine evolutionary gap driven by weak selection pressure:

  • Rare substrate in any individual lifespan: Glucosepane accumulates slowly over decades in long-lived organisms; its abundance in any given organism at the time of maximum reproductive output (when selection pressure is highest) is low. Selection for glucosepane-specific repair enzymes was weak.
  • Soil saprophyte solution bypasses crosslink chemistry: Soil microbes that catabolize aged glycated proteins use broad-specificity proteases and collagenases to fragment the polypeptide backbone around crosslinks rather than cleaving crosslink chemistry itself. This achieves nutrient recovery (releasing amino acids from flanking residues) without requiring crosslink-specific enzyme evolution. The functional metagenomics premise assumes the selective pressure exists; the saprophyte evidence suggests it may not.
  • Thermodynamic stability of mature crosslinks: Glucosepane contains a fused imidazo[4,5-b]pyridinium ring system; pentosidine contains a pyridinium cross-bridge. Both are thermodynamically stable heterocyclic structures — activation energies for enzymatic hydrolysis are high. Evolution of a catalytic active site capable of selectively attacking these chemistries without off-target protein damage would require a sophisticated active-site geometry.

Implication: An effective ECM AGE-clearing therapy probably cannot rely on discovering a naturally occurring glucosepane-cleaving enzyme. The more tractable strategies may be: (a) discovering a novel enzyme in previously unexplored metagenomes or deep-sea/extremophile microbiomes; (b) engineering a designer enzyme de novo using computational protein design; or (c) chemistry-based cleavage agents (small molecules or synthetic chemistry) that bypass biological enzyme constraints.

Alagebrium (ALT-711) — the clinical pioneer

Background and mechanism

Alagebrium chloride (ALT-711; 4,5-dimethyl-3-phenacylthiazolium chloride; PubChem CID 216305) was developed by Alteon Inc. as a thiazolium-based small molecule intended to cleave α-dicarbonyl-derived AGE crosslinks via nucleophilic attack on the crosslink backbone. It is the lead clinical candidate of the thiazolium class, derived from the prototype N-phenacylthiazolium bromide (PTB), first described by Vasan et al. 8.

Preclinical record

Alagebrium and its predecessors showed substantial positive functional readouts in preclinical models across three mammalian species:

ModelAgentKey finding
Aged mongrel dogsALT-711Reversed age-related increases in myocardial (LV) stiffness; ~40% reduction in chamber stiffness constant (57.1→33.1 mmHg·m²/ml, P<0.001); improved stroke volume index 8
STZ-diabetic rats, 1–3 wkALT-711Reversed diabetes-induced large-artery stiffness (compliance, aortic impedance, carotid distensibility) 9
Aging diabetic rat heartALT-711Reduced cardiac collagen, improved LV function, normalized collagen type I/III expression 10
STZ-diabetic rat myocardiumALT-711Attenuated diabetes-induced myocardial changes; restored LVEF without reducing blood glucose 11

Clinical program

Phase 2 signal: Little et al. 2005 reported that alagebrium 420 mg/day × 16 weeks in n=21 elderly patients with diastolic heart failure reduced left ventricular mass and improved diastolic filling (E’ velocity) 12. Phase 2 arterial stiffness signals in hypertensive patients were also reported 13.

Phase 3 failure (BENEFICIAL trial): Hartog et al. 2011 — the pivotal randomized, double-blind, placebo-controlled BENEFICIAL trial (n=102, systolic heart failure [LVEF ≤0.45], alagebrium 200 mg BID × 36 weeks) — showed no improvement in peak VO₂ (primary endpoint: P=0.06, NS), diastolic function (E’, P=0.32), systolic function (LVEF, P=0.43), NYHA class, or quality of life vs placebo 14. The clinical development program was discontinued ~2009–2011.

DimensionStatus
Phase 2 signalYes — arterial stiffness and diastolic HF (small n)
Phase 3 replicationNo — BENEFICIAL null on all endpoints
Enrolled population appropriate?Uncertain — BENEFICIAL enrolled systolic HF (LVEF ≤0.45), not HFpEF; crosslink-mediated diastolic dysfunction is the more mechanistically motivated target
ECM crosslink cleavage confirmed in humans?No direct evidence

Why alagebrium probably failed — two compounding problems

Problem 1 — Wrong target crosslink. Alagebrium was designed to cleave α-dicarbonyl-derived crosslinks. But glucosepane — the dominant human ECM crosslink — is NOT an α-dicarbonyl crosslink. It forms via a distinct non-oxidative cyclization mechanism. If alagebrium cannot cleave glucosepane, it was attacking a minor target while the dominant structural problem accumulated untouched. This mechanistic mismatch was identified by the SENS Research Foundation and Spiegel lab researchers as the primary motivation for glucosepane-specific chemistry.

Problem 2 — The Yang 2003 critique: model compounds vs. real-tissue crosslinks. Yang, Litchfield & Baynes 2003 tested PTB, the alagebrium pharmacophore (PMT), and pyridoxamine against (a) an in-vitro phenylpropanedione model crosslink and (b) real Maillard crosslinks in skin and tail tendon collagen from STZ-diabetic rats 15. The diabetic-rat collagen carried ~5× (skin) and ~10× (tail tendon) the crosslinking burden of controls.

The result, verbatim: “although AGE-breakers and PM cleave model crosslinks, they do not significantly cleave AGE crosslinks formed in vivo in skin collagen of diabetic rats.”

This is a class-level critique: all three compounds — PTB, alagebrium pharmacophore, AND pyridoxamine — failed against real tissue-formed crosslinks. It implies that the positive preclinical functional readouts (reduced arterial compliance, improved cardiac function, reduced AGE immunoreactivity) in the alagebrium table above are likely mediated by non-crosslink-breaking mechanisms: RAGE-axis modulation, reactive-carbonyl scavenging (preventing new crosslink formation rather than reversing existing ones), anti-inflammatory effects, or direct effects on resident cells.

Combined interpretation: Alagebrium was designed for the wrong crosslink chemistry AND likely never achieved genuine crosslink cleavage even for its stated target. The positive in-vivo functional signals are pharmacologically real but probably reflect indirect cardiovascular effects rather than structural ECM repair. This explains why Phase 2 cardiovascular surrogate signals did not translate to Phase 3 functional endpoints in established heart failure.

contradictory-evidence — Yang 2003 directly conflicts with the positive preclinical functional papers listed above. The conflict is resolved by distinguishing functional surrogate readouts from direct crosslink-mass measurement; Yang 2003 is the only paper to date that measured actual crosslink cleavage in real-tissue collagen, and the result was null for all tested agents. needs-replication for Yang 2003 (single study at abstract-level verification; full PDF closed-access pending).

TRC4186 — Phase 1 candidate

TRC4186 (pyridinium AGE-breaker; Torrent Pharmaceuticals) showed preclinical cardiovascular benefits in obese hypertensive rats (Ob-ZSF1 model) — improved diastolic relaxation, reduced afterload, and lower AGE load 16 — and advanced to Phase 1 establishing oral safety, tolerability, and dose-proportional kinetics 17. No subsequent peer-reviewed clinical development has been published through 2026-05-19. The program appears stalled at Phase 1. TRC4186 falls under the same Yang 2003 critique as alagebrium-class agents (pyridinium-ring chemistry; whether it cleaves real-tissue glucosepane crosslinks is not established). needs-replication

Modern glucosepane-specific breakers (Spiegel Lab / Revel Pharmaceuticals)

The rational-chemistry shift

The 2015 total synthesis of glucosepane by Draghici, Wang, and Spiegel at Yale (8 steps, 12% yield, enantioselective) was a landmark that enabled creation of synthetic glucosepane immunogens and the first antibody tools for direct tissue detection 18. Prior to this synthesis, glucosepane could only be quantified by mass spectrometry after protein hydrolysis.

Streeter et al. 2020 (Spiegel/McDonald/Taylor labs) used these antibody tools to demonstrate direct immunohistochemical detection of glucosepane in aging mouse retinal tissue — specifically in the retinal pigment epithelium, Bruch’s membrane, and choroid, where it colocalizes with lipofuscin in regions associated with age-related macular degeneration 19. needs-human-replication — direct human retinal glucosepane localization not yet published. This confirmed glucosepane accumulation in a clinically important tissue with limited access to existing measurement methods.

In 2022, the Spiegel group reported pentosinane — a previously undercharacterized stable AGE post-translational modification structurally related to pentosidine and glucosepane — via a separate JACS paper (deRamon et al. 2022) 20. This expands the known landscape of stable in-vivo AGE modifications beyond the previously characterized glucosepane + pentosidine set, relevant to the question of whether a single crosslink-breaker would suffice or a portfolio approach is required. Note: whether pentosinane functions as a bifunctional inter-chain crosslink (as glucosepane does) is not established from published data — this distinction matters for drug-target prioritization. needs-replication

Revel Pharmaceuticals

Revel Pharmaceuticals (Yale spinoff, founded 2018, San Francisco; co-founders David Spiegel, Jason Crawford, and Shyam Bhattacharya Cravens) was established to advance glucosepane-cleaving therapeutics. The original R&D strategy was functional metagenomics — searching soil microbial genomes for enzymes capable of degrading synthetic glucosepane, on the premise that soil microbes evolve to catabolize glycated proteins as nutrient sources.

Reproducibility setback and strategic pivot. Industry-watcher reporting from 2024 indicates that the glucosepane-cleaving activity of the initial Spiegel lab enzyme candidates could not be reproduced, prompting Revel to broaden its scope beyond glucosepane alone 7. Per disclosed Revel leadership statements: the company now describes a portfolio of five or six target crosslinks and damage products rather than glucosepane exclusively. needs-primary-source-verification — this claim is sourced to a commenter on a Fight Aging blog post, not a peer-reviewed paper or official Revel disclosure; treat as industry-watcher-grade information pending primary confirmation.

Current status (mid-2026): Preclinical. No clinical candidate has been disclosed in peer-reviewed literature. No IND has been filed. No clinical trial is registered on ClinicalTrials.gov. The roadmap disclosed by Revel in 2021 (human cadaver tissue from biobanks → animal models → clinical) does not appear to have produced a peer-reviewed animal-efficacy paper to date.

No published in-vivo glucosepane-cleavage efficacy data exists from any program as of 2026-05-19. The technical barrier is substantial: glucosepane is a stable imidazolium crosslink embedded within the triple-helical collagen scaffold; selective enzymatic cleavage in vivo without off-target effects on other Lys/Arg-containing proteins is a formidable challenge. needs-human-replication

DimensionStatus
Glucosepane total synthesisDone (Draghici 2015) 18
Antibody tools for tissue detectionDone (Streeter 2020) — in aging mouse retinae 19
In-vitro enzyme-mediated glucosepane cleavageClaimed (Spiegel lab, pre-Revel); reproducibility challenged
In-vivo animal-model efficacyNot published as of 2026-05-19
Clinical candidate disclosedNo
Clinical trial registeredNo

Alternative strategies — scope comparison

Three other AGE-targeting pharmacological strategies should be distinguished from AGE-crosslink breaking:

StrategyMechanismKey compoundsStatusDistinct from breaking?
AGE formation inhibitorsTrap reactive dicarbonyl intermediates upstream of crosslink formationAminoguanidine, pyridoxamine, benfotiamineAminoguanidine Phase 3 halted (toxicity); pyridoxamine stalled at Phase 2/3; benfotiamine mixed Phase 2Yes — prevent new crosslinks, do not cleave existing ones
AGE-RAGE pathway modulatorsBlock RAGE receptor signaling (NF-κB → inflammation)sRAGE decoys, small-molecule RAGE antagonistsPreclinical for aging; no aging-indication RCTYes — target signaling arm, not structural damage
Collagen turnover accelerationIncrease MMP-driven ECM remodeling to dilute AGE-loaded collagen over timeLOX inhibition (see lox), TGF-β modulationNo clinical aging programYes — very slow; does not cleave established crosslinks
AGE-crosslink breakersCleave established covalent crosslinks in existing collagenAlagebrium (failed), Revel/Spiegel (preclinical)Preclinical onlyThis class

Important note on pyridoxamine and the Yang 2003 result: Pyridoxamine was designed as an AGE formation inhibitor (reactive-carbonyl trap). Yang et al. 2003 tested it alongside alagebrium-class agents and confirmed it also does NOT cleave real-tissue Maillard crosslinks — consistent with its upstream mechanism 15. Pyridoxamine belongs in the antioxidant class, NOT age-crosslink-cleavage.

Measurement biomarkers for clinical trials

Any future AGE-crosslink-breaker trial will require validated biomarker endpoints to measure target engagement:

BiomarkerWhat it measuresStrengthsLimitations
Skin autofluorescence (SAF) via skin-autofluorescence-age-reader (AGE Reader; DiagnOptics)Bulk fluorescent AGEs in dermis (pentosidine + cross-reactive species)Non-invasive; validated vs biopsy; predicts CV and mortality outcomes 21Does not distinguish glucosepane specifically; confounded by skin pigmentation
Skin biopsy + LC-MS glucosepaneGlucosepane pmol/mg collagen (gold standard)Direct quantification; validated by Sell 2005 1Invasive; research-only; sampling variability
Urinary glucosepane (Spiegel lab DCCT/EDIC tool)Free glucosepane excretedNon-invasive; Spiegel lab method for DCCT/EDIC studiesNot commercially validated; research assay only
Pulse wave velocity (PWV)Functional readout of arterial stiffnessEstablished clinical tool; correlates with glucosepane cross-sectionally 2Indirect (multiple contributors); confounded by blood pressure, hydration
Plasma glucosepane (GSPN)Circulating free glucosepane; used in DCCT/EDIC 22Accessible; associates with diabetic complications after HbA1c adjustmentReflects soluble, not tissue-bound crosslinks
Skin collagen pepsin-solubilityCrosslink burden assay (as used in Yang 2003) 15Direct crosslink measure in research modelsBiopsy-derived; requires ex-vivo processing; no validated human clinical version

A robust breaker trial would need: (1) skin biopsy glucosepane at baseline and endpoint; (2) SAF as a non-invasive surrogate; (3) PWV as a functional cardiovascular readout; (4) cardiac MRI for diastolic function if targeting HFpEF; (5) target-tissue engagement demonstration (urinary glucosepane as turnover signal).

SENS / hallmark mapping

FrameCategoryStatus
SENSGlycoSENS — extracellular crosslinksHighest-priority unmet GlycoSENS challenge; no clinical agent as of 2026
López-Otín hallmarksloss-of-proteostasis (ECM structural-protein homeostasis); secondary: altered-intercellular-communication (mechanosensing disruption)Not a primary hallmark target; ECM crosslinking has no dedicated hallmark in 2013/2023 framework
Intervention tractabilityLow — no validated druggable approach for the dominant (glucosepane) crosslinkdruggability-tier: null / tier 3 at best (predicted enzymatically tractable; no validated probe)

Aging-context evidence summary

Evidence levelFinding
In vitro (model crosslinks)Alagebrium-class compounds cleave in-vitro model crosslinks 15
In vivo — preclinical (functional)Alagebrium reversed arterial and myocardial stiffness in rodents and dogs 8 9 10; likely mediated by non-crosslink mechanisms
In vivo — preclinical (crosslink)No compound has demonstrated cleavage of real-tissue Maillard crosslinks in vivo 15
In vivo — preclinical (glucosepane-specific)No published glucosepane-cleavage efficacy data exists from any program as of 2026-05-19
Human Phase 2Alagebrium showed arterial stiffness and diastolic HF signals (small n, surrogate endpoints) 12 13
Human Phase 3BENEFICIAL (alagebrium, systolic HF, n=102): null on all endpoints 14
Human Phase 3 — HFpEFNot done; most mechanistically motivated population has never been tested

Limitations and open questions

  • No validated in-vivo crosslink-cleavage chemistry exists for the dominant (glucosepane) crosslink. The foundational challenge of cleaving a stable imidazolium crosslink embedded in packed collagen fibrils without off-target protein damage is unsolved. no-mechanism for in-vivo cleavage
  • Alagebrium’s positive preclinical record is mechanistically orphaned. The functional preclinical signals are real but Yang 2003 raises the possibility that none of them reflect genuine ECM crosslink reversal. Reconciling this requires direct crosslink-mass measurement in the preclinical models — data that do not appear to exist. contradictory-evidence
  • HFpEF has never been tested. BENEFICIAL enrolled systolic HF (LVEF ≤0.45). The population with mechanistically motivated crosslink-dependent diastolic dysfunction (HFpEF, stiff LV, high AGE burden) has not been enrolled in a definitive trial. needs-human-replication
  • Revel Pharmaceuticals’ glucosepane-enzyme reproducibility setback is unconfirmed at peer-reviewed level. The pivot to a multi-crosslink portfolio may reduce scientific focus. needs-primary-source-verification
  • Non-invasive tissue glucosepane measurement for clinical endpoint tracking does not exist. SAF is a surrogate for fluorescent AGEs broadly, not glucosepane specifically. Direct tissue measurement requires skin biopsy + LC-MS. no-mechanism for non-invasive endpoint
  • Crosslink contribution fraction to age-related arterial stiffness is not established quantitatively — titin crosslinks, elastin calcification, endothelial dysfunction, and other mechanisms co-contribute. no-mechanism for relative weighting
  • Long-term safety of any glucosepane-specific enzyme is unknown — would require demonstration of tissue specificity, immunogenicity profiling, and absence of off-target ECM disruption. long-term-unknown
  • Diabetes vs. aging context. Most clinical evidence is from diabetic populations with accelerated crosslink accumulation. Whether interventions effective in diabetes-accelerated crosslink burden would translate to normoglycemic aging remains unknown. needs-human-replication

Cross-references

Footnotes

Footnotes

  1. doi:10.1074/jbc.M500733200 · Sell DR et al. · J Biol Chem 2005;280(13):12310–15 · ex-vivo · model: human skin collagen (n=110) + glomerular basement membrane (n=28) · glucosepane is the dominant AGE crosslink by mass in adult human ECM; ~2000 pmol/mg at age 90 (nondiabetic); 2–3× elevated in diabetes; ~10–100× pentosidine by mass (from cross-paper comparison) · archive: status pending download PMID:15677467 ↩ ↩2

  2. doi:10.1016/j.jdiacomp.2014.12.011 · Sveen KA et al. · J Diabetes Complications 2015 · observational · n=27 T1D (40-year duration) + 24 controls · skin glucosepane correlated with cIMT (r=0.41) and PWV (r=0.44) independent of HbA1c · archive: not_oa ↩ ↩2

  3. doi:10.1016/j.matbio.2013.09.004 · Gautieri A, Redaelli A, Buehler MJ, Vesentini S · Matrix Biol 2014 · in-silico · model: human type I collagen triple helix · identified 14 Lys–Arg pairs likely to form glucosepane; crosslink sites overlap integrin, proteoglycan, and collagenase binding sites on collagen ↩

  4. doi:10.1042/bst0311343 · Thornalley PJ · Biochem Soc Trans 2003;31(Pt 6):1343–8 · PMID:14641060 · review · GLO1 mechanism and intracellular methylglyoxal steady-state ~1–5 µM; age-related decline documented · archive: closed-access (not_oa) · no-fulltext-access ↩ ↩2

  5. doi:10.1042/BJ20060684 · Veiga da-Cunha M, Jacquemin P, Delpierre G, Godfraind C, Théate I, Vertommen D, Clotman F, Lemaigre F, Devuyst O, Van Schaftingen E · Biochem J 2006;399(2):257–64 · PMID:16819943 · in-vivo · FN3K-KO mice: ~2.5× elevated erythrocyte fructosamine; phenotypically normal under normoglycemia · archive: OA bronze; download pending ↩

  6. doi:10.3390/ijms25094779 · Delanghe JR, Diana Di Mavungu J, Beerens K, Himpe JJ, Bostan N, Speeckaert MM, Vrielinck H, Vral A, Van Den Broeke C, Huizing M, Van Aken E · Int J Mol Sci 2024;25(9):4779 · PMID:38732004 · ex-vivo · glycolaldehyde-glycated porcine retinas + human AMD retinal sections · AGE autofluorescence reduced (p=0.001); drusen surface area 45 ± 21% of control; substrate scope includes CML, CEL, imidazolone by MS; glucosepane/pentosidine cleavage NOT reported · archive: OA gold; download pending · abstract-only verification; full PDF required no-fulltext-access ↩

  7. Industry-watcher source — NOT peer-reviewed literature. URL: https://www.fightaging.org/archives/2021/10/an-update-on-revel-pharmaceuticals-working-on-glucosepane-cross-link-breakers/ · 2021 Fight Aging article on Revel Pharmaceuticals updated by reader comments through 2024 · key claim (glucosepane-enzyme reproducibility failure) is sourced to a commenter, not to Revel or peer-reviewed literature · Revel leadership’s scope-expansion statement (five or six target crosslinks) is corroborated by Longevity.Technology and Lifespan.io coverage · needs-primary-source-verification — confirm via official Revel disclosure, SEC/IPO filing, or peer-reviewed paper before treating as established fact ↩ ↩2

  8. doi:10.1073/pnas.040558497 · Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR et al. · PNAS 2000;97(6):2809–13 · in-vivo · model: aged mongrel dogs (n=8 treated, n=5 control, n=7 young) · ALT-711 (1 mg/kg/day oral × 4 wk) reduced LV chamber stiffness constant ~40% (57.1±6.8 → 33.1±4.6 mmHg·m²/ml, P<0.001); improved stroke volume index (P<0.05); no change in EF or blood pressure · archive: downloaded PMID:10706607 ↩ ↩2 ↩3

  9. doi:10.1073/pnas.95.8.4630 · Wolffenbuttel BHR et al. · PNAS 1998;95(8):4630–4 · in-vivo · model: STZ-diabetic rats · ALT-711 (1–10 mg/kg/day) reversed diabetes-induced large-artery stiffness (systemic arterial compliance, aortic impedance, carotid distensibility) · archive: status pending download PMID:9539791 ↩ ↩2

  10. PMID:12946933 · Liu J, Masurekar MR, Vatner DE et al. · Am J Physiol Heart Circ Physiol 2003;285(6):H2587–91 · in-vivo · model: aging diabetic rat heart · alagebrium reduced cardiac collagen, improved cardiac function, normalized type I/III collagen expression · abstract-level — verification pending ↩ ↩2

  11. doi:10.1161/01.res.0000065620.39919.20 · Candido R et al. · Circulation Research 2003;92(7):785–92 · in-vivo · model: STZ-diabetic rat myocardium · ALT-711 attenuated diabetes-induced myocardial changes; restored LVEF; no glucose lowering · abstract-level — verification pending ↩

  12. doi:10.1016/j.cardfail.2004.09.010 · Little WC, Zile MR, Kitzman DW et al. · J Card Fail 2005 · rct · n=21 · mean age 71 years · diastolic HF · alagebrium 420 mg/day × 16 weeks; reduced LV mass, improved E’ velocity, improved QoL; no change in EF or arterial compliance · archive: not_oa ↩ ↩2

  13. doi:10.1016/j.amjhyper.2004.08.022 · Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S · Am J Hypertens 2004 · review · summary of Phase 2 alagebrium evidence for arterial stiffness and diastolic HF; characterizes safety as well-tolerated ↩ ↩2

  14. doi:10.1093/eurjhf/hfr067 · Hartog JW et al. (BENEFICIAL investigators) · Eur J Heart Fail 2011;13(8):899–908 · rct · n=102 · systolic HF (LVEF ≤0.45) · alagebrium 200 mg BID × 36 wk vs placebo · primary endpoint (peak VO₂): −2.1±0.5 vs −0.5±0.7 mL/min/kg (P=0.06, NS) · all secondary endpoints NS · archive: status pending download PMID:21669961 ↩ ↩2

  15. PMID:12646266 · Yang S, Litchfield JE, Baynes JW · Arch Biochem Biophys 2003;412(1):42–6 · ex-vivo · model: skin + tail tendon collagen from STZ-diabetic rats (in-vivo-formed Maillard crosslinks) + in-vitro phenylpropanedione model crosslink · compounds: PTB (alagebrium prototype), PMT (alagebrium pharmacophore), pyridoxamine · result: all three compounds cleaved the in-vitro model crosslink but NONE decreased crosslink burden in real-tissue diabetic collagen (pepsin solubilization half-time and tail-tendon acid insolubility unchanged) · direct quote: “although AGE-breakers and PM cleave model crosslinks, they do not significantly cleave AGE crosslinks formed in vivo in skin collagen of diabetic rats” · abstract-level verification via PubMed 2026-05-19; full PDF closed-access pending · load-bearing class-level critique covering PTB, alagebrium pharmacophore, AND pyridoxamine simultaneously ↩ ↩2 ↩3 ↩4 ↩5

  16. doi:10.1097/FJC.0b013e3181ac3a34 · Joshi D et al. · J Cardiovasc Pharmacol 2009;54(1):72–81 · in-vivo · model: obese Zucker spontaneously hypertensive fatty rats (type-2 diabetic phenotype) · TRC4186 (27 mg/kg BID IP) prevented BP rise, improved cardiac output via diastolic relaxation + systolic emptying, reduced AGE load · abstract-level via PubMed PMID:19546815 ↩

  17. doi:10.2165/11315260-000000000-00000 · Pandhi P et al. · Clin Drug Investig 2009;29(8):505–17 · rct (Phase 1) · healthy volunteers, single + multiple dose escalation · oral TRC4186 well-tolerated; dose-proportional kinetics; steady state 6 days; safe across ages/sexes/races · abstract-level — no subsequent clinical development reported through 2026-05-19 ↩

  18. doi:10.1126/science.aac9655 · Draghici C, Wang T, Spiegel DA · Science 2015;350(6258):294–8 · synthetic chemistry · first total synthesis of glucosepane (confirmed via Crossref: 8 steps, 12% yield, enantioselective) · enabled production of synthetic immunogens and antibody tools; underpinned the Revel research program · archive: closed-access (not_oa); claims verified via Crossref metadata + Spiegel lab corroborating publications PMID:26472902 no-fulltext-access ↩ ↩2

  19. doi:10.1021/acschembio.0c00093 · Streeter MD, Rowan S, Ray J, McDonald DM, Volkin J, Clark J, Taylor A, Spiegel DA · ACS Chem Biol 2020;15(10):2655–61 · in-vitro + ex-vivo · model: aging mouse retinae (immunohistochemistry) · first direct IHC detection of glucosepane in RPE, Bruch’s membrane, and choroid; colocalizes with lipofuscin; antibodies validated via ELISA against synthetic AGE derivatives · NOT human retinal tissue — human applicability inferred but not directly demonstrated · archive: status pending download (OA via PMC) PMID:32975399 ↩ ↩2

  20. doi:10.1021/jacs.2c09626 · deRamon EA, Sabbasani VR, Streeter MD, Liu Y, Newhouse TR, McDonald DM, Spiegel DA · J Am Chem Soc 2022;144(48):21843–7 · synthetic chemistry · first total synthesis of pentosinane (7 steps, 1.7% yield, enantioselective); characterized as a “nonenzymatic post-translational modification” structurally related to pentosidine and glucosepane; described as a stable AGE modification; note: abstract describes pentosinane as a single-protein PTM; whether it functions as a bifunctional inter-chain crosslink (like glucosepane) is not established from abstract alone · confirmed authors + title via Crossref · PMID:36410375 needs-replication ↩

  21. doi:10.1038/s41598-024-71037-7 · [authors pending confirmation] · Sci Rep 2024 · observational · population-based cohort · skin autofluorescence independently predicted cause-specific mortality · archive: status pending download needs-primary-source-verification — authors and cohort size need confirmation against primary source ↩

  22. doi:10.1136/bmjdrc-2021-002667 · Monnier VM et al. (DCCT/EDIC Research Group) · BMJ Open Diabetes Res Care 2022;10(1):e002667 · observational · n=466 DCCT/EDIC participants · plasma glucosepane (GSPN) associated with PDR (p≤0.02) and confirmed clinical neuropathy (p<0.003) after HbA1c adjustment PMID:35058313 ↩

Graph View

Backlinks